

**AN ARTICLE ON COLON TARGETED DRUG DELIVERY SYSTEM****Syed Gouse Firoz\*, Dr.J.N.Suresh Kumar, Shaik.Abdul Saleem, Shaik Munwar**

Assistant Professor, Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences, Kotappa Konda Road, Yalamanda Post, Narasaraopeta-522601, Guntur District, Andhra Pradesh.

**\*Corresponding Author: Syed Gouse Firoz**

Assistant Professor, Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences, Kotappa Konda Road, Yalamanda Post, Narasaraopeta-522601, Guntur District, Andhra Pradesh.

Article Received on 28/03/2018

Article Revised on 18/04/2018

Article Accepted on 08/05/2018

**ABSTRACT**

Day by day there are new developments in field of colon specific drug delivery system. Colonic drug delivery has gained increased importance not just for the delivery of the drugs for the treatment of local diseases associated with the colon like Crohn's disease, ulcerative colitis, etc. but also for the systemic delivery of proteins, therapeutic peptides, anti-asthmatic drugs, antihypertensive drugs and anti-diabetic agents. New systems and technologies have been developed for colon targeting and to overcome previous method's limitations. Colon targeting holds a great potential and still need more innovative work.

**KEYWORDS:** Colon Drug Delivery, Crohn's disease.**INTRODUCTION**

Targeted drug delivery into the colon is highly desirable for local treatment of a variety of bowel diseases such as ulcerative colitis, Crohn's disease, amebiasis, colonic cancer, local treatment of colonic pathologies, and systemic delivery of protein and peptide drugs. The colon specific drug delivery system (CDDS) should be capable of protecting the drug en route to the colon i.e. drug release and absorption should not occur in the stomach as well as the small intestine, and neither the bioactive agent should be degraded in either of the dissolution sites but only released and absorbed once the system reaches the colon. The colon is believed to be a suitable absorption site for peptides and protein drugs for the following reasons; (i) less diversity, and intensity of digestive enzymes, (ii) comparative proteolytic activity of colon mucosa is much less than that observed in the small intestine, thus CDDS protects peptide drugs from hydrolysis, and enzymatic degradation in duodenum and jejunum, and eventually releases the drug into ileum or colon which leads to greater systemic bioavailability and finally, because the colon has a long residence time which is up to 5 days and is highly responsive to absorption enhancers.

Oral route is the most convenient and preferred route but other routes for CDDS may be used. Rectal administration offers the shortest route for targeting drugs to the colon. However, reaching the proximal part of colon via rectal administration is difficult. Rectal administration can also be uncomfortable for patients and

compliance may be less than optimal. Drug preparation for intrarectal administration is supplied as solutions, foam, and suppositories. The intrarectal route is used both as a means of systemic dosing and for the delivery of topically active drug to the large intestine. Corticosteroids such as hydrocortisone and prednisolone are administered via the rectum for the treatment of ulcerative colitis. Although these drugs are absorbed from the large bowel, it is generally believed that their efficacy is due mainly to the topical application. The concentration of drug reaching the colon depends on formulation factors, the extent of retrograde spreading and the retention time. Foam and suppositories have been shown to be retained mainly in the rectum and sigmoid colon while enema solutions have a great spreading capacity.

Because of the high water absorption capacity of the colon, the colonic contents are considerably viscous and their mixing is not efficient, thus availability of most drugs to the absorptive membrane is low. The human colon has over 400 distinct species of bacteria as resident flora, a possible population of up to 10<sup>10</sup> bacteria per gram of colonic contents. Among the reactions carried out by these gut flora are azoreduction and enzymatic cleavage i.e. glycosides. These metabolic processes may be responsible for the metabolism of many drugs and may also be applied to colon-targeted delivery of peptide based macromolecules such as insulin by oral administration.

**Target sites, colonic disease conditions, and drugs used for treatment**

Target sites	Disease conditions	Drug and active agents
Topical action	Inflammatory Bowel Diseases, Irritable bowel disease and Crohn's disease. Chronic pancreatitis	Hydrocortisone, Budesonide, Prednisolone, Sulfasalazine, Olsalazine, Mesalazine, Balsalazide.
Local action	Pancreatotomy and cystic fibrosis, Colorectal cancer	Digestive enzyme supplements 5-Flourouracil.
Systemic action	To prevent gastric irritation To prevent first pass metabolism of orally ingested drugs Oral delivery of peptides Oral delivery of vaccines	NSAIDS Steroids Insulin Typhoid

**Advantages of CDDS over Conventional Drug Delivery**

Chronic colitis, namely ulcerative colitis, and Crohn's disease are currently treated with glucocorticoids, and other anti-inflammatory agents. Administration of glucocorticoids namely dexamethasone and methyl prednisolone by oral and intravenous routes produce systemic side effects including adenosuppression, immunosuppression, cushinoid symptoms, and bone resorption. Thus selective delivery of drugs to the colon

could not only lower the required dose but also reduce the systemic side effects caused by high doses.

**Criteria for Selection of Drug for CDDS**

The best Candidates for CDDS are drugs which show poor absorption from the stomach or intestine including peptides. The drugs used in the treatment of IBD, ulcerative colitis, diarrhea, and colon cancer are ideal candidates for local colon delivery.

Criteria	Pharmacological class	Non-peptide drugs	Peptide drugs
Drugs used for local effects in colon against GIT diseases	Anti-inflammatory drugs	Oxyprenolol, Metoprolol, Nifedipine	Amylin, Antisense oligonucleotide
Drugs poorly absorbed from upper GIT	Antihypertensive and antianginal drugs	Ibuprofen, Isosorbides, Theophylline	Cyclosporine, Desmopressin
Drugs for colon cancer	Antineoplastic drugs	Pseudoephedrine	Epoetin, Glucagon
Drugs that degrade in stomach and small intestine	Peptides and proteins	Bromophenaramine, 5-Flourouracil, Doxorubicin	Gonadoreline, Insulin, Interferons
Drugs that undergo extensive first pass metabolism	Nitroglycerin and corticosteroids	Bleomycin, Nicotine	Protirelin,sermorelin, Saloatonin
Drugs for targeting	Antiarthritic and antiasthamatic drugs	Prednisolone, hydrocortisone, 5-Amino-salicylic acid	Somatropin, Urotoilitin

**Approaches used for Site Specific Drug Delivery to Colon (CDDS)**

Several approaches are used for site-specific drug delivery. Among the primary approaches for CDDS, These include

**1) Primary Approaches for CDDS****a. pH Sensitive Polymer Coated Drug Delivery to the Colon**

In the stomach, pH ranges between 1 and 2 during fasting but increases after eating. The pH is about 6.5 in the proximal small intestine, and about 7.5 in the distal small intestine. From the ileum to the colon, pH declines significantly. It is about 6.4 in the cecum. However, pH values as low as 5.7 have been measured in the ascending colon in healthy volunteers. The pH in the transverse colon is 6.6 and 7.0 in the descending colon. Use of pH dependent polymers is based on these differences in pH levels. The polymers described as pH dependent in colon specific drug delivery are insoluble at low pH levels but become increasingly soluble as pH rises. Although a pH dependent polymer can protect a formulation in the stomach, and proximal small intestine, it may start to dissolve in the lower small intestine, and

the site-specificity of formulations can be poor. The decline in pH from the end of the small intestine to the colon can also result in problems, lengthy lag times at the ileo-cecal junction or rapid transit through the ascending colon which can also result in poor site-specificity of enteric-coated single-unit formulations.

**b. Delayed (Time Controlled Release System) Release Drug Delivery to Colon**

Time controlled release system (TCRS) such as sustained or delayed release dosage forms are also very promising drug release systems. However, due to potentially large variations of gastric emptying time of dosage forms in humans, in these approaches, colon arrival time of dosage forms cannot be accurately predicted, resulting in poor colonic availability. The dosage forms may also be applicable as colon targeting dosage forms by prolonging the lag time of about 5 to 6 h. However, the disadvantages of this system are:

1. Gastric emptying time varies markedly between subjects or in a manner dependent on type and amount of food intake.

2. Gastrointestinal movement, especially peristalsis or contraction in the stomach would result in change in gastrointestinal transit of the drug.
3. Accelerated transit through different regions of the colon has been observed in patients with the IBD, the carcinoid syndrome and diarrhea, and the ulcerative colitis.

### c. Microbially Triggered Drug Delivery to Colon

The microflora of the colon is in the range of 10<sup>11</sup> -10<sup>12</sup> CFU/mL, consisting mainly of anaerobic bacteria, e.g. bacteroides, bifidobacteria, eubacteria, clostridia, enterococci, enterobacteria and ruminococcus etc. This vast microflora fulfills its energy needs by fermenting various types of substrates that have been left undigested in the small intestine, e.g. di- and tri-saccharides, polysaccharides etc. For this fermentation, the microflora produces a vast number of enzymes like glucuronidase, xylosidase, arabinosidase, galactosidase, nitroreductase, azareductase, deaminase, and urea dehydroxylase. Because of the presence of the biodegradable enzymes only in the colon, the use of biodegradable polymers for colon-specific drug delivery seems to be a more site-specific approach as compared to other approaches. These polymers shield the drug from the environments of stomach and small intestine, and are able to deliver the drug to the colon. On reaching the colon, they undergo assimilation by micro-organism, or degradation by enzyme or break down of the polymer backbone leading to a subsequent reduction in their molecular weight and thereby loss of mechanical strength. They are then unable to hold the drug entity any longer.

#### i) Prodrug Approach for Drug Delivery to Colon

Prodrug is a pharmacologically inactive derivative of a parent drug molecule that requires spontaneous or enzymatic transformation *in vivo* to release the active drug. For colonic delivery, the prodrug is designed to undergo minimal hydrolysis in the upper tracts of GIT, and undergo enzymatic hydrolysis in the colon there by releasing the active drug moiety from the drug carrier. Metabolism of azo compounds by intestinal bacteria is one of the most extensively studied bacterial metabolic process. A number of other linkages susceptible to bacterial hydrolysis specially in the colon have been prepared where the drug is attached to hydrophobic moieties like amino acids, glucuronic acids, glucose, galactose, cellulose etc. Limitations of the prodrug approach is that it is not a very versatile approach as its formulation depends upon the functional group available on the drug moiety for chemical linkage.

#### (ii) Azo-Polymeric Prodrugs

Newer approaches are aimed at the use of polymers as drug carriers for drug delivery to the colon. Both synthetic as well as naturally occurring polymers have been used for this purpose. Sub synthetic polymers have been used to form polymeric prodrug with azo linkage between the polymer and drug moiety. These have been

evaluated for CDDS. Various azo polymers have also been evaluated as coating materials over drug cores. These have been found to be similarly susceptible to cleavage by the azoreductase in the large bowel. Coating of peptide capsules with polymers cross linked with azoaromatic group have been found to protect the drug from digestion in the stomach and small intestine. In the colon, the azo bonds are reduced, and the drug is released.

#### iii) Polysaccharide Based Delivery Systems

The use of naturally occurring polysaccharides is attracting a lot of attention for drug targeting the colon since these polymers of monosaccharides are found in abundance, have wide availability are inexpensive and are available in a variety of structures with varied properties. They can be easily modified chemically, biochemically, and are highly stable, safe, nontoxic, hydrophilic and gel forming and in addition, are biodegradable. These include naturally occurring polysaccharides obtained from plant (guar gum, inulin), animal (chitosan, chondroitin sulphate), algal (alginates) or microbial (dextran) origin. The polysaccharides can be broken down by the colonic microflora to simple saccharides. Therefore, they fall into the category of "generally regarded as safe" (GRAS).

### Newly Developed Approaches for CDDS

#### a. Pressure Controlled Drug-Delivery Systems

As a result of peristalsis, higher pressures are encountered in the colon than in the small intestine. Takaya *et al.* developed pressure controlled colon-delivery capsules prepared using ethylcellulose, which is insoluble in water. In such systems, drug release occurs following the disintegration of a water-insoluble polymer capsule because of pressure in the lumen of the colon. The thickness of the ethylcellulose membrane is the most important factor for the disintegration of the formulation. The system also appeared to depend on capsule size and density. Because of reabsorption of water from the colon, the viscosity of luminal content is higher in the colon than in the small intestine. It has therefore been concluded that drug dissolution in the colon could present a problem in relation to colon-specific oral drug delivery systems. In pressure controlled ethylcellulose single unit capsules the drug is in a liquid. Lag times of three to five hours in relation to drug absorption were noted when pressure-controlled capsules were administered to humans.

#### b. Novel Colon Targeted Delivery System (CODESTM)

CODESTM is a unique CDDS technology that was designed to avoid the inherent problems associated with pH or time dependent systems. CODESTM is a combined approach of pH dependent and microbially triggered CDDS. It has been developed by utilizing a unique mechanism involving lactulose, which acts as a trigger for site specific drug release in the colon. The system consists of a traditional tablet core containing

lactulose, which is over coated with an acid soluble material, Eudragit E, and then subsequently overcoated with an enteric material, Eudragit L. The premise of the technology is that the enteric coating protects the tablet while it is located in the stomach and then dissolves quickly following gastric emptying. The acid soluble material coating then protects the preparation as it passes through the alkaline pH of the small intestine. Once the tablet arrives in the colon, the bacteria enzymatically degrade the polysaccharide (lactulose) into organic acid. This lowers the pH surrounding the system sufficient to effect the dissolution of the acid soluble coating and subsequent drug release.

### c. Osmotic Controlled Drug Delivery (ORDS-CT)

The OROS-CT (Alza corporation) can be used to target the drug locally to the colon for the treatment of disease or to achieve systemic absorption that is otherwise unattainable. The OROS-CT system can be a single osmotic unit or may incorporate as many as 5-6 push-pull units, each 4 mm in diameter, encapsulated within a hard gelatin capsule. Each bilayer push pull unit contains an osmotic push layer and a drug layer, both surrounded by a semipermeable membrane. An orifice is drilled through the membrane next to the drug layer. Immediately after the OROS-CT is swallowed, the gelatin capsule containing the push-pull units dissolves. Because of its drug-impermeable enteric coating, each push-pull unit is prevented from absorbing water in the acidic aqueous environment of the stomach, and hence no drug is delivered. As the unit enters the small intestine, the coating dissolves in this higher pH environment (pH >7), water enters the unit, causing the osmotic push compartment to swell, and concomitantly creates a flowable gel in the drug compartment. Swelling of the osmotic push compartment forces drug gel out of the orifice at a rate precisely controlled by the rate of water transport through the semipermeable membrane. For treating ulcerative colitis, each push pull unit is designed with a 3-4 h post gastric delay to prevent drug delivery in the small intestine. Drug release begins when the unit reaches the colon. OROS-CT units can maintain a constant release rate for up to 24 hours in the colon or can deliver drug over a period as short as four hours. Recently, new phase transited systems have come which promise to be a good tool for targeting drugs to the colon. Various in vitro / in vivo evaluation techniques have been developed and proposed to test the performance and stability of CDDS.

For in vitro evaluation, not any standardized evaluation technique is available for evaluation of CDDS because an ideal in vitro model should possess the in-vivo conditions of GIT such as pH, volume, stirring, bacteria, enzymes, enzyme activity, and other components of food. Generally, these conditions are influenced by the diet, physical stress, and these factors make it difficult to design a slandered in-vitro model. In vitro models used for CDDS are

### a) In vitro dissolution test

Dissolution of controlled-release formulations used for colon-specific drug delivery are usually complex, and the dissolution methods described in the USP cannot fully mimic in vivo conditions such as those relating to pH, bacterial environment and mixing forces. Dissolution tests relating to CDDS may be carried out using the conventional basket method. Parallel dissolution studies in different buffers may be undertaken to characterize the behavior of formulations at different pH levels. Dissolution tests of a colon-specific formulation in various media simulating pH conditions and times likely to be encountered at various locations in the gastrointestinal tract have been studied. The media chosen were, for example, pH 1.2 to simulate gastric fluid, pH 6.8 to simulate the jejunal region of the small intestine, and pH 7.2 to simulate the ileum segment. Enteric-coated capsules for CDDS have been investigated in a gradient dissolution study in three buffers. The capsules were tested for two hours at pH 1.2, then one hour at pH 6.8, and finally at pH 7.4.

### b) In vitro enzymatic tests

Incubate carrier drug system in fermenter containing suitable medium for bacteria (*Streptococcus faecium* and *B. Ovatus*). The amount of drug released at different time intervals are determined. Drug release study is done in buffer medium containing enzymes (e.g. pectinase, dextranase), or rat or guinea pig or rabbit cecal contents. The amount of drug released in a particular time is determined, which is directly proportional to the rate of degradation of polymer carrier.

### c) In vivo evaluation

A number of animals such as dogs, guinea pigs, rats, and pigs are used to evaluate the delivery of drug to colon because they resemble the anatomic and physiological conditions as well as the microflora of human GIT. While choosing a model for testing a CDDS, relative model for the colonic diseases should also be considered. Guinea pigs are commonly used for experimental IBD model. The distribution of azoreductase and glucuronidase activity in the GIT of rat and rabbit is fairly comparable to that in the human. For rapid evaluation of CDDS, a novel model has been proposed. In this model, the human fetal bowel is transplanted into a subcutaneous tunnel on the back of thymic nude mice, which vascularizes within four weeks, matures, and becomes capable of developing of mucosal immune system from the host.

### Drug Delivery Index (DDI) and Clinical Evaluation of Colon-Specific Drug Delivery Systems

DDI is a calculated pharmacokinetic parameter, following single or multiple dose of oral colonic prodrugs. DDI is the relative ratio of RCE (Relative colonic tissue exposure to the drug) to RSC (Relative amount of drug in blood i.e. that is relative systemic exposure to the drug). High drug DDI value indicates better colon drug delivery. Absorption of drugs from the

colon is monitored by colonoscopy and intubation. Currently, gamma scintigraphy and high frequency capsules are the most preferred techniques employed to evaluate colon drug delivery systems.

#### REFERENCES

1. Philip AK, Dabas S, Pathak K. Optimized prodrug approach: a means for achieving enhanced anti-inflammatory potential in experimentally induced colitis.
2. Oluwatoyin AO, John TF. In vitro evaluation of khaya and albizia gums as compression coating for drug targeting to the colon.
3. Akala EO, Elekwachi O, Chase V, Johnson H, Lazarre M, Scott K. Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery.
4. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems.
5. Basit A, Bloor J. Perspectives on colonic drug delivery.
6. Watts P, Illum L. Colonic drug delivery.
7. Wood E, Wilson CG, Hardy JG. The spreading of foam and solution.
8. Chien YW. Oral drug delivery and delivery systems. In: Chien YW, editor. Novel drug delivery systems.
9. Reddy SM, Sinha VR, Reddy DS. Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs.